Organon (OGN) EPS (Basic) Growth (3y) (2023 - 2026)
Organon (OGN) EPS (Basic) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.01 Bn | 633.25 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 469.88 Bn | 463.31 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 376.95 Bn | 369.81 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 258.13 Bn | 253.23 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 236.66 Bn | 222.67 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 183.33 Bn | 180.15 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 160.34 Bn | 148.64 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | -34.06% |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | -24.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.29% |
| Mar 31, 2026 | -6.94% |
| Jun 30, 2024 | 268.49% |
| Mar 31, 2024 | 267.96% |
| Dec 31, 2023 | 311.71% |
| Sep 30, 2023 | 85.91% |
| Jun 30, 2023 | 95.40% |
| Mar 31, 2023 | 97.38% |